PF-06835919

N/A

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NamePF-06835919
Drug Alias NamePF-06835919
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFructokinases inhibitors
TargetsFructokinases
Therapy Area/IndicationsHepatic InsufficiencyMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesN/A
Active IndicationsHepatic Insufficiency
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A